Asmik Mkrtychyan
Detroit, MINPI 1295024743
Payments from drug & device makers
Across 126 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$351
- Novo Nordisk$281
- AstraZeneca$232
- Pfizer$206
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$199
- Otsuka America Pharmaceutical, Inc.$91
- plus $733 from 17 others
What the payments were for
- Food & beverage$2,093100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $351 |
| Novo Nordisk | 18 | $281 |
| AstraZeneca | 14 | $232 |
| Pfizer | 12 | $206 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $199 |
| Otsuka America Pharmaceutical, Inc. | 5 | $91 |
| Merck | 6 | $90 |
| GSK | 5 | $76 |
| Sumitomo Pharma America, Inc. | 3 | $68 |
| Amgen | 4 | $65 |
| Boehringer Ingelheim | 3 | $59 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Lilly USA, LLC | 3 | $43 |
| Lundbeck LLC | 2 | $42 |
| Bayer | 3 | $41 |
| Indivior Inc. | 2 | $31 |
| Edwards Lifesciences | 1 | $29 |
| Exact Sciences | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Ardelyx, Inc. | 1 | $14 |
| UCB, Inc. | 1 | $14 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 77 | $62,565 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $55,772 |
| OzempicSemaglutide | 56 | $55,266 |
| TrulicityDulaglutide | 53 | $51,655 |
| JardianceEmpagliflozin | 58 | $43,356 |
| EliquisApixaban | 33 | $21,691 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $14,781 |
| XareltoRivaroxaban | 20 | $13,030 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $12,306 |
| EntrestoSacubitril/Valsartan | 11 | $10,828 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $9,466 |
| JanuviaSitagliptin Phosphate | 11 | $8,848 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 220 | $5,531 |
| VascepaIcosapent Ethyl | 13 | $4,676 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 21 | $2,385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $232 | $77,34695 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $76 | $68,078103 claims |
| Novo NordiskOzempic | $281 | $55,26656 claims |
| Lilly USA, LLCTrulicity | $43 | $51,65553 claims |
| Boehringer IngelheimJardiance | $59 | $43,35658 claims |
| PfizerEliquis | $206 | $21,69133 claims |
| MerckJanuvia | $90 | $8,84811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Michiganon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.